Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EmbraceRX vs LaSara Medical Group

EmbraceRX
Graded #363

Higher grade

vs+4.100000000000001
LaSara Medical Group
Graded #455

Lower grade

The verdict

EmbraceRX takes it — 58.6/100 to 54.5/100.

EmbraceRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EmbraceRX (Embrace Rx) is a clinician-guided telehealth platform offering pharmacy-compounded medications prescribed online, partnered with the Samaritan MD physician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbraceRX +12
45
33
Dose & formulationLaSara Medical Group +8
56
64
Clinical oversightEmbraceRX +7
76
69
Labs & monitoringLaSara Medical Group +1
52
53
FulfillmentEmbraceRX +7
73
66
Contract termsEmbraceRX +8
55
47
EmbraceRX · left barLaSara Medical Group · right bar

The numbers

MetricEmbraceRXLaSara Medical Group
WeighScore58.6/10054.5/100
GradeCC
Scorecard rank#363#455
SemaglutideNot disclosed$289/mo (compounded)
TirzepatideNot disclosed$399/mo (bundle, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
EmbraceRX

Graded #363 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)
LaSara Medical Group

Graded #455 · C

Strengths

  • Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
  • National telehealth plus an in-person option in Southern California — uncommon hybrid model
  • Free initial consultation
  • Active promotional pricing (30% off sitewide at the time of review)
  • GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy partner not named
  • LegitScript certification status not confirmed
  • Per-state availability not listed despite the national-telehealth claim
  • Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard